↑ 薬物リストへ　← 戻る

Syntocinon    (DrugBank: -)

3 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病1
127前頭側頭葉変性症1
193プラダー・ウィリ症候群7

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-002877-23-AT
(EUCTR)		21/01/201907/12/2018Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study.Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD Social functioning in Parkinson's disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Syntocinon 40 IU/ml nasal spray
INN or Proposed INN: Synthetic Oxytocin
Other descriptive name: OXYTOCIN SYNTHETIC		Abteilung für Neurologie der Medizinischen Universität InnsbruckNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		76Phase 2Austria

127. 前頭側頭葉変性症　［臨床試験数：74，薬物数：83（DrugBank：28），標的遺伝子数：29，標的パスウェイ数：99］
Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 74 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03260920
(ClinicalTrials.gov)		January 31, 201819/7/2017Intranasal Oxytocin for Frontotemporal DementiaA Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal DementiaFrontotemporal DementiaDrug: SyntocinonLawson Health Research InstituteWeston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry ConsultantsRecruiting30 Years80 YearsAll112Phase 2United States;Canada

193. プラダー・ウィリ症候群　［臨床試験数：95，薬物数：104（DrugBank：27），標的遺伝子数：50，標的パスウェイ数：63］
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 95 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2017-003423-30-NL
(EUCTR)		12/12/201704/10/2017Intranasal administration of oxytocin in children with Prader-Willi syndromeRandomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome.Effects on social behaviour. Prader-Willi syndrome
MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Trade Name: Syntocinon nasal spray
Product Name: oxytocin
Product Code: oxytocin		Dutch Growth Research FoundationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		33Phase 2;Phase 3Netherlands
2EUCTR2016-003820-22-NL
(EUCTR)		22/12/201612/10/2016Intranasal administration of oxytocin in children with Prader-Willi SyndromeIntranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating behaviour and social behaviour. - Intranasal administration of oxytocin in children with PWS Prader-Willi syndrome
MedDRA version: 19.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Trade Name: Syntocinon nasal spray
Product Name: oxytocin
Product Code: oxytocin		Dutch Growth Research FoundationNULLNot RecruitingFemale: yes
Male: yes		Phase 3Netherlands
3EUCTR2016-003273-18-FR
(EUCTR)		14/11/201622/08/2016Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years.Effects of intranasal administrations of oxytocin on beahvioural troubles, hyperphagia and social skills in children with Prader-Willi syndrome aged from 3 to 12 years. - OXYJEUNE Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: SyntocinonUniversity Hospital of ToulouseNULLNot RecruitingFemale: yes
Male: yes		40Phase 3France
4EUCTR2013-004134-15-NL
(EUCTR)		15/07/201420/03/2014Intranasal administration of oxytocin in children and young-adults with Prader-Willi syndromeIntranasal administration of oxytocin in children and young adults with Prader-Willi Syndrome. A randomized, double-blind, placebo-controlled trial. Effects on satiety and food intake, and social behaviour. - Intranasal administration of oxytocin in PWS Prader-Willi syndrome
MedDRA version: 17.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Trade Name: Syntocinon nasal spray
Product Name: oxytocin
Product Code: oxytocin		Dutch Growth Research FoundationNULLNot RecruitingFemale: yes
Male: yes		Phase 3Netherlands
5EUCTR2013-004437-33-FR
(EUCTR)		18/03/201408/09/2015Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-WilliEffets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi. - PRADOTIM Prader-Willi syndrom
MedDRA version: 18.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Trade Name: SyntocinonCentre Hospitalier de ToulouseNULLNot RecruitingFemale: yes
Male: yes		39Phase 3France
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT01038570
(ClinicalTrials.gov)		June 200916/11/2009Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus PlaceboEvaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot StudyPrader Willi SyndromeDrug: Syntocinon®/- Spray;Drug: Physiological serum (Sodium chloride)University Hospital, ToulouseNULLCompleted18 YearsN/AAll24Phase 2France
7EUCTR2010-022370-14-FR
(EUCTR)		15/11/2010Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBBEvaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBB Syndrome de Prader Willi
MedDRA version: 12.1;Level: LLT;Classification code 10036476;Term: Prader-Willi syndrome		Trade Name: SyntocinonCentre Hospitalier de ToulouseNULLNAFemale: yes
Male: yes		Phase 2France

先頭へ